Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Follow us on LinkedIn and X.SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler's 36th Annual Healthcare Conference.
聖地亞哥，2024年11月25日（全球新聞社）-- Boundless Bio（納斯達克：BOLD）是一家臨床階段的腫瘤學公司，正在研究細胞外染色體DNA（ecDNA）生物學，以爲以前難以治癒的癌基因擴增癌症患者提供變革性療法。今天宣佈，總裁兼首席執行官扎卡里·霍恩比將參加派傑投資第36屆年度醫療會議。
A fireside chat session is scheduled for Wednesday, December 4, 2024, in New York, NY, at 3:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website and can be accessed via this link: .
火爐邊聊天環節定於2024年12月4日星期三，在紐約，紐約州，下午3:30（東部時間）舉行。本次會議的現場直播和歸檔網絡直播將在Boundless Bio網站投資者部分的「活動與演示」下可供訪問，鏈接爲：。
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio's second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has an additional program (ecDTx 3) advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.
For more information, visit .
關於Boundless Bio
Boundless Bio是一家臨床階段的腫瘤學公司，致力於解鎖癌症治療的新範式，以滿足癌基因擴增腫瘤患者的重大未滿足需求，目標是細胞外染色體DNA（ecDNA），這是在超過14%的癌症患者中觀察到的癌基因擴增的根本原因。Boundless Bio正在開發首個面向ecDNA的療法（ecDTx），BBI-355，這是一種口服檢查點激酶1（CHK1）抑制劑，目前正在針對癌基因擴增癌症患者進行I/II期臨床試驗。Boundless Bio的第二個ecDTx，BBI-825，是一種口服核苷酸還原酶（RNR）抑制劑，目前正在針對有BRAFV600E或KRASG12C突變和耐藥基因擴增的結直腸癌患者進行I/II期臨床試驗。利用其Spyglass平台，Boundless Bio還有一個額外的項目（ecDTx 3）正在進行臨床前開發和發現。Boundless Bio總部位於加利福尼亞州聖地亞哥。
欲了解更多信息，請訪問網站。
Follow us on LinkedIn and X.
關注我們的領英和X頁面。
Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
聯繫方式：
本·弗勞姆，無限生物
bflaum@boundlessbio.com
Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com
投資者
THRUST戰略通訊
Renee Leck
renee@thrustsc.com
譯文內容由第三人軟體翻譯。
